biological source
rabbit
Quality Level
antibody form
serum
antibody product type
primary antibodies
clone
polyclonal
form
liquid
species reactivity
human
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
dilution
(Immunoblotting (1:5000-1:20,000)
Immunofluorescence (1:1000)
Immunohistochemistry (1:1000)
Immunoprecipitation (1:1000))
isotype
IgG
shipped in
ambient
storage temp.
−20°C
target post-translational modification
unmodified
General description
兔多克隆抗体以未稀释的血清形式提供。识别全长APP和C端可溶性产物CTFγ（~6 kDa）、CTFα（~9 kDa）和CTFβ（~11 kDa）。
兔多克隆抗淀粉样蛋白前体蛋白C末端（751-770）可识别全长APP和C末端可溶性产物CTFα，β和γ。经验证可用于WB、IF、IHC和IP。
识别全长APP和C端可溶性产物CTFγ（~6 kDa）、CTFα（~9 kDa）和CTFβ（~11 kDa）。抗体靶基因符号：APP 靶标异名：AAA，AD1，Adap，AL024401，淀粉样蛋白前体，淀粉样蛋白糖蛋白，APP异构体1，APPI，appican，CTFgamma，CVAP，E030013M08RIK，Nexin II，P3，PN2，PreA4，蛋白酶 NEXIN2 Entrez基因名称：淀粉样β（A4）前体蛋白 Hu Entrez ID：351（相关抗体：PC729, PC152,PC151, PC150, PC149, NE1012,171609, 171608, 171607, 171606, 171605, 171604, 171603, 171598, 171537) Mu Entrez ID: 11820 大鼠Entrez ID：54226
Immunogen
人
合成肽[(C)KMQQNGYENPTYKFFEQMQN]，对应于人前体蛋白（APP）的751-770位氨基酸，与KLH偶联
Application
免疫印迹（1:5000-1:20,000）
免疫荧光（1:1000）
免疫组织化学（1:1000）
免疫沉淀（1:1000）
免疫荧光（1:1000）
免疫组织化学（1:1000）
免疫沉淀（1:1000）
Preparation Note
初次融化后，等分并冷冻（-20°C）。
Other Notes
Pinnix, I., et al. 2001.J. Biol. Chem.276, 481.
合适的工作稀释度由与测定条件相关的变量决定。
Legal Information
采购本材料仅供研究使用。在将0433抗体或任何衍生物用于临床诊断或治疗目的之前，请用户向Mayo索取许可证。有关许可信息，请联系：Mayo Medical Ventures，技术商业化办公室（507）284-8878，200 First Street SW，Rochester，MN 55905-001。
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
毒性：标准处理（A）
Still not finding the right product?
试用我们的 产品选型工具 工具缩小选择范围
存储类别
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Inderjeet Saluja et al.
Neurobiology of disease, 36(1), 162-168 (2009-07-28)
The neuronal adaptor protein X11alpha/mint-1/APBA-1 binds to the cytoplasmic domain of the amyloid precursor protein (APP) to modulate its trafficking and metabolism. We investigated the consequences of reducing X11alpha in a mouse model of Alzheimer's disease (AD). We crossed hAPPswe/PS-1DeltaE9
Ramon Velazquez et al.
Aging cell, 18(6), e13037-e13037 (2019-09-29)
Currently, there are no effective therapies to ameliorate the pathological progression of Alzheimer's disease (AD). Evidence suggests that environmental factors may contribute to AD. Notably, dietary nutrients are suggested to play a key role in mediating mechanisms associated with brain
Xiqian Lan et al.
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 7(2), 412-423 (2011-08-10)
Combined antiretroviral therapy (ART) tremendously improved the lifespan and symptoms associated with AIDS-defining illness in affected individuals. However, chronic ART-treated patients frequently develop age-dependent complications, including dementia, diabetes, and hyperlipidemia: all risk factors of Alzheimer's disease. Importantly, the effect of
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 171610-50UL | 07790788048150 |